A Study to Evaluate the Effectiveness of MEDI-563 in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

Study identifier:MI-CP196

ClinicalTrials.gov identifier:NCT01227278

EudraCT identifier:2010-020127-52

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects with Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia

Medical condition

Pulmonary Disease, Chronic Obstructive

Phase

Phase 2

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

421

Study type

Interventional

Age

40 Years - 85 Years

Date

Study Start Date: 01 Nov 2010
Primary Completion Date: 01 Jan 2013
Study Completion Date: 01 Jul 2013

Study design

Allocation: Randomized
Endpoint Classification: Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2015 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

AstraZeneca

Inclusion and exclusion criteria